Robinhood chain to generate $160M in annual fees by 2028: Bernstein
Trading platform Robinhood’s blockchain network is expected to generate as much as $160 million in annual fees by 2028, Bernstein analysts forecast in a Tuesday report shared with Cointelegraph.
The analysts cited growing demand for tokenized stock trading on the network, which grew to account for about 27% of the chain’s total trading volume, while native memecoin pairs trading decreased to 36% of network activity, down from 100% at launch on July 1.
Bernstein said the growing demand for tokenized stocks on the Robinhood chain is driven by automated market-making pools on Uniswap that pair memecoins with stock tokens and create “reflexive demand” for both sides.
In a little more than two months since launch, the Robinhood chain has emerged as the leading blockchain network by daily fees, generating $2.13 million in the past 24 hours, according to DefiLlama.
On July 20, Bernstein raised its price target on Robinhood (HOOD) stock to $160 from $130 per share and maintained its Outperform rating, forecasting growth in the platform’s prediction market business and tokenized equities. The company’s Nasdaq-traded shares were little changed at last look in Tuesday’s premarket activity, according to Yahoo Finance data.
However, Robinhood’s blockchain-based equities recently drew criticism from Adam Aron, CEO of AMC Entertainment Holdings, who said the platform’s tokenized stocks providing economic exposure to AMC shares have no affiliation with the company. Aron called the offering “outrageous” and said that AMC will request an investigation from its outside securities counsel.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
